EcoDrugPlus

Hypocretin (Orexin) Receptor 2

Ensembl ID : ENSLACG00000001750
Gene Symbol: HCRTR2
4 Cross references
167 Possible Orthologues:

Hypocretin Receptor 1

Ensembl ID : ENSLACG00000011960
Gene Symbol: HCRTR1
2 Cross references
96 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 1

Ensembl ID : ENSLACG00000008301
Gene Symbol: IMPDH1
4 Cross references
331 Possible Orthologues:

Inosine Monophosphate Dehydrogenase 2

Ensembl ID : ENSLACG00000003907
Gene Symbol: IMPDH2
3 Cross references
200 Possible Orthologues:

Inositol Polyphosphate-5-Phosphatase D

Ensembl ID : ENSLACG00000013057
Gene Symbol: INPP5D
4 Cross references
215 Possible Orthologues:

Insulin Like Growth Factor 1 Receptor

Ensembl ID : ENSLACG00000007108
Gene Symbol: IGF1R
3 Cross references
274 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSLACG00000004756
Gene Symbol: LOC102358202
1 Cross references
287 Possible Orthologues:

Insulin Receptor

Ensembl ID : ENSLACG00000009952
Gene Symbol: INSR
3 Cross references
287 Possible Orthologues:

Integrin Alpha-V-Like

Ensembl ID : ENSLACG00000000563
Gene Symbol: LOC102346778
3 Cross references
242 Possible Orthologues:

Integrin Beta-1

Ensembl ID : ENSLACG00000003676
Gene Symbol: LOC102349081
3 Cross references
298 Possible Orthologues:

Integrin Subunit Alpha 4

Ensembl ID : ENSLACG00000014426
Gene Symbol: ITGA4
4 Cross references
236 Possible Orthologues:

Integrin Subunit Beta 1

Ensembl ID : ENSLACG00000001067
Gene Symbol: ITGB1
3 Cross references
298 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).